文献速递肾癌与肾肿瘤

腹膜后与经腹腔机器人辅助部分肾切除术的随机对照可行性试验:ROPARN研究

Randomised controlled feasibility trial of retroperitoneal vs transperitoneal robot-assisted partial nephrectomy: the ROPARN study.
PubMed 文献 · BJU Int · 2025-01-22

单中心、开放标签、可行性随机对照试验,将疑似局限性肾细胞癌拟行机器人部分肾切除术的患者按1:1随机分配至经腹腔机器人部分肾切除术(TRPN)或腹膜后机器人部分肾切除术(RRPN),共61例接受手术(RRPN 31例 vs TRPN 30例)。RRPN在手术时间、控制台时间等方面显示时间优势,术后活动度、疼痛和肠道功能方面数值更优但无统计学显著差异,两组阳性手术切缘率、缺血时间、出血和并发症无显著差异。

要点

  • RRPN较TRPN手术时间更短(81 vs 105 min,P=0.005),控制台时间更短(49 vs 73 min,P<0.001)。
  • RRPN术后24小时内活动度77% vs TRPN 71%(P=0.613),术后疼痛评分RRPN 1.5 vs TRPN 1.8(P=0.509),均无统计学显著差异。
  • 两组阳性手术切缘率、缺血时间、出血和并发症无统计学显著差异。

核心结论

  • RRPN显示出显著的时间优势,是TRPN的安全替代方案,阳性手术切缘率相似。
  • RRPN组术后并发症数值上更少,但无统计学显著差异。
  • 作者认为这些结果强调背外侧肾肿瘤应优先采用RRPN切除。
  • 作者指出需要进一步的多中心随机对照试验来确认这些结果。

研究设计与样本

  • 单中心、开放标签、可行性随机对照试验。
  • 疑似局限性肾细胞癌拟行机器人部分肾切除术的患者按1:1随机分配至TRPN或RRPN。
  • 共61例患者接受TRPN或RRPN(31例 vs 30例)。
  • 主要结局为试验可行性、术后活动度和疼痛感知;次要结局为术中时间、并发症评估和阳性手术切缘率比较。
  • 对所有接受手术的随机患者数据进行描述性分析。

主要发现

  • 术后24小时内活动度RRPN 77% vs TRPN 71%(P=0.613),差异无统计学显著。
  • 术后疼痛数字评分中位数RRPN 1.5 vs TRPN 1.8(P=0.509),差异无统计学显著。
  • 术后3天内肠道完全通畅RRPN 100% vs TRPN 90%(P=0.315),差异无统计学显著。
  • RRPN较TRPN手术时间更短(81 vs 105 min,P=0.005),控制台时间更短(49 vs 73 min,P<0.001),从控制台到肾动脉准备时间更短(7.5 vs 18 min,P<0.001)。
  • TRPN从皮肤切开到控制台时间更短(16 vs 12 min,P=0.001)。

关键数值与推荐

  • 术后24小时内活动度:RRPN 77% vs TRPN 71%(P=0.613)。
  • 术后疼痛数字评分中位数:RRPN 1.5 vs TRPN 1.8(P=0.509)。
  • 术后3天内肠道完全通畅:RRPN 100% vs TRPN 90%(P=0.315)。
  • 手术时间:RRPN 81 min vs TRPN 105 min(P=0.005)。
  • 控制台时间:RRPN 49 min vs TRPN 73 min(P<0.001)。

临床怎么用

  • 作者认为背外侧肾肿瘤应优先采用RRPN切除。
  • 作者指出RRPN是TRPN的安全替代方案,具有时间优势且阳性手术切缘率相似。
  • 作者指出需要进一步的多中心随机对照试验来确认这些结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the feasibility of trial recruitment and confirm that retroperitoneal robotic partial nephrectomy (RRPN) has the same oncological efficacy as transperitoneal robotic partial nephrectomy (TRPN), with time advantages and less peri-operative morbidity, in a randomised controlled trial (RCT). PATIENTS AND METHODS: The study was designed as a single-centre, open-label, feasibility RCT. Patients with suspected localised renal cell carcinoma referred for robotic partial nephrectomy were randomised in a 1:1 ratio to receive either TRPN or RRPN. The primary outcomes were trial feasibility, postoperative mobility and pain perception. Secondary outcomes were intra-operative times, assessment of complications, and comparison of positive surgical margin (PSM) rates. The data on all randomised patients who underwent surgery were analysed descriptively. RESULTS: Sixty-one patients underwent TRPN or RRPN (31 vs 30). Postoperative mobility within 24 h after surgery (RRPN: 77 vs TRPN: 71%; P = 0.613), median postoperative pain, assessed using a numeric rating scale (RRPN: 1.5 vs TRPN: 1.8; P = 0.509), and full bowel canalisation within 3 days (RRPN: 100% vs TRPN: 90%; P = 0.315) were more favourable in the RRPN group, but the difference was not statistically significant. In comparison to TRPN, RRPN was associated with shorter operating time (81 vs 105 min; P = 0.005), shorter time on the console (49 vs 73 min; P < 0.001) and shorter time from console to renal artery preparation (7.5 vs 18 min; P < 0.001). TRPN required a shorter time from skin incision to console (16 vs 12 min; P = 0.001). There was no statistically significant difference in tumour complexity, ischaemia time, PSM rate, blood loss or complications between the two groups. CONCLUSION: We present the first data from an RCT comparing RRPN with TRPN. RRPN showed significant time benefits while being a safe alternative to TRPN, with a similar PSM rate. There was less postoperative morbidity in the RRPN group, although this was not statistically significant. These results underline that dorsolateral renal tumours should be preferably resected by RRPN. Further multicentre RCTs are necessary to confirm these results.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kälble S, Engelmann SU, Schrutz H, et al. Randomised controlled feasibility trial of retroperitoneal vs transperitoneal robot-assisted partial nephrectomy: the ROPARN study. BJU Int. 2025. PMID: 39840817. doi:10.1111/bju.16653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。